Summary & Overview
CPT 0466U: CardioRisk+ Polygenic Risk Assessment for Acquired Heart Disease
CPT code 0466U designates a proprietary laboratory analysis for the CardioRisk+ test from Gene by Gene Ltd. and OpenDNA Ltd. The test combines DNA from a buccal swab with patient lifestyle and clinical data to generate an algorithmic polygenic risk estimate for acquired heart disease. As a PLA code tied to a single manufacturer and test, 0466U is relevant for payers and providers navigating coverage, medical necessity review, and billing for genomic risk assessments.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national-level overview of where this code fits in clinical workflows and billing systems, plus what to expect when encountering 0466U on claims. The publication outlines typical sites of service and the clinical context for use—genetic susceptibility assessment using buccal swab specimens—as well as common operational considerations for payer adjudication and claim submission.
This analysis provides benchmarks and policy context relevant to genomic proprietary tests, summaries of payer coverage posture where available, and practical coding information to support billing professionals and laboratory administrators handling claims for CardioRisk+ under CPT code 0466U.
Billing Code Overview
CPT code 0466U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the CardioRisk+ test from Gene by Gene Ltd. and OpenDNA Ltd. The test analyzes DNA collected via a buccal (cheek) swab and integrates genetic data with patient lifestyle and clinical information to produce an algorithmic assessment of polygenic risk for acquired heart disease. This reporting reflects an individual’s genetic susceptibility to heart disease rather than a diagnostic result for current disease.
Service type: Proprietary laboratory genetic risk analysis
Typical site of service: Clinical laboratory or diagnostic laboratory processing specimens collected in outpatient settings (buccal swab collection)
Clinical & Coding Specifications
Clinical Context
A 52-year-old adult with a family history of premature coronary artery disease and elevated lifetime cardiovascular risk requests genomic risk assessment. The clinician orders the CardioRisk+ proprietary test to quantify polygenic susceptibility to acquired heart disease. The patient presents to an outpatient clinic or a certified phlebotomy center; a buccal (cheek) swab sample is collected per manufacturer instructions, demographic and lifestyle data (smoking status, BMI, diet, physical activity) and relevant clinical data (personal history of hypertension, hyperlipidemia, diabetes, current medications) are recorded and securely transmitted to the testing laboratory (Gene by Gene Ltd. / OpenDNA Ltd.). The laboratory performs DNA extraction, genotyping, and an algorithmic analysis that integrates genomic markers with the supplied lifestyle and clinical variables to produce a polygenic risk score for acquired heart disease. Test results are returned to the ordering clinician with an interpretation report indicating relative genetic risk compared to population norms. Typical sites of service include outpatient primary care clinics, cardiology clinics, preventive medicine clinics, and certified laboratory specimen collection centers. Billing uses the PLA code 0466U to report the CardioRisk+ test. Common clinical uses include risk stratification discussions, shared decision-making about preventive strategies, and informing consideration of early lifestyle or pharmacologic interventions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |